Vancouver, BC, February 1, 2022--Bold Therapeutics, a clinical-stage biopharmaceutical company developing BOLD-100, announced an extension of the option agreement with Hana Pharm, a leading South Korean biopharmaceutical company, originally executed in May 2020 for development and commercialization rights to BOLD-100 in South Korea.
|